Abstract
Purpose:We evaluated the relationship between isocitrate dehydrogenase 1 (IDH1) mutation status and metabolic imaging in patients with nonenhancing supratentorial diffuse gliomas using 11C-methionine positron emission tomography (11C-MET PET).Materials and Methods:Between June 2012 and November 2017, we enrolled 86 (38 women and 48 men; mean age, 41.9 ± 13.1 years [range, 8-67 years]) patients with newly diagnosed supratentorial diffuse gliomas. All patients underwent preoperative 11C-MET PET. Tumor samples were obtained and immunohistochemically analyzed for IDH1 mutation status.Results:The mutant and wild-type IDH1 diffuse gliomas had significantly different mean maximum standardized uptake value values (2.73 [95% confidence interval, CI: 2.32-3.16] vs 3.85 [95% CI: 3.22-4.51], respectively; P = .004) and mean tumor-to-background ratio (1.90 [95% CI: 1.65-2.16] vs 2.59 [95% CI: 2.17-3.04], respectively; P = .007).Conclusions: 11C-methionine PET can noninvasively evaluate the IDH1 mutation status of patients with nonenhancing supratentorial diffuse gliomas.
Highlights
Cerebral gliomas are the most common primary malignant brain tumors, accounting for 29% of all primary and 81% of all malignant brain tumors.[1]
The mutant and wild-type isocitrate dehydrogenase 1 (IDH1) diffuse gliomas had significantly different mean maximum standardized uptake value values (2.73 [95% confidence interval, CI: 2.32-3.16] vs 3.85 [95% CI: 3.22-4.51], respectively; P 1⁄4 .004) and mean tumor-tobackground ratio (1.90 [95% CI: 1.65-2.16] vs 2.59 [95% CI: 2.17-3.04], respectively; P 1⁄4 .007)
Given the value of noninvasive preoperative evaluation of molecular biomarkers for clinical applications, we evaluated the relationship between 11C-MET PET uptake and IDH1 in patients with newly diagnosed diffuse supratentorial gliomas
Summary
Cerebral gliomas are the most common primary malignant brain tumors, accounting for 29% of all primary and 81% of all malignant brain tumors.[1] Previously, prognostic evaluations were based on the histological features of tumor tissues along with clinical variables, such as age and performance status. The clinical outcomes have greatly varied among patients regardless of having the same pathological classification. The histopathological classification of gliomas has a long history, it has high interobserver and intraobserver variability and does not adequately predict clinical outcomes. Several biomarkers have been discovered to play vital roles in tumor differentiation. Molecular characterizations have become even more relevant, with mutations of isocitrate dehydrogenase (IDH), tumor protein 53 (TP53), and a-thalassemia/mental retardation syndrome X-linked (ATRX); 1p/19q codeletion; and O6-methylguanine-DNA methyltransferase
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
